| Patient | Arthur Ashe |
|---|---|
| Date of birth | 1943-07-10 |
| Identifiers | MRN HR-ML013-SYN-TD; SSN (made up) 000-13-6620 |
| Document date | 2026-11-01 |
| Author | Vivian Tolliver, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for HIV after a recent diagnosis with cerebral toxoplasmosis, and for coronary artery disease after two bypass operations. Concerns: He wants to decide for himself who learns of his HIV diagnosis, and when; He wants to keep coaching and playing tennis without putting his heart at risk. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, one tablet by mouth once daily; take two hours before or six hours after antacids, calcium, iron, or magnesium | One tablet by mouth once daily | Oral route | 1988-09-25 | active | S |
| Pyrimethamine 25 mg oral tablet, 200 mg once, then three tablets (75 mg) by mouth daily for six weeks; course completed before intake | Three tablets by mouth daily after a 200 mg loading dose | Oral route | 1988-09-11 to 1988-10-23 | completed | S |
| Sulfadiazine 500 mg oral tablet, three tablets (1500 mg) by mouth every 6 hours for six weeks; course completed before intake | Three tablets by mouth every 6 hours | Oral route | 1988-09-11 to 1988-10-23 | completed | S |
| Leucovorin 10 mg oral tablet, two tablets (20 mg) by mouth daily with pyrimethamine; course completed before intake | Two tablets by mouth daily | Oral route | 1988-09-11 to 1988-10-23 | completed | S |
| Sulfamethoxazole 800 mg and trimethoprim 160 mg (double strength), one tablet by mouth twice daily | One tablet by mouth twice daily | Oral route | 1988-10-23 to 1989-10-19 | completed | S |
| Aspirin 81 mg delayed-release oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1979-07-31 | active | S |
| Atorvastatin 80 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1979-08-01 | active | S |
| Ezetimibe 10 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 1989-01-12 | active | S |
| Nitroglycerin 0.4 mg sublingual tablet, one tablet under the tongue every 5 minutes as needed for chest pain, up to 3 tablets; call 911 if pain is not better 5 minutes after the first tablet | One tablet under the tongue every 5 minutes as needed for chest pain, up to 3 doses | Sublingual route | 1979-08-01 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Coronary artery bypass grafting, four grafts, after a myocardial infarction at age 36 | 1979-12-13 to 1979-12-13 | completed | S |
| Repeat coronary artery bypass grafting, two grafts, for recurrent angina; blood transfusion given | 1983-06-15 to 1983-06-15 | completed | S |
| MRI of the head with contrast: single ring-enhancing lesion in the left frontoparietal region with surrounding edema | 1988-09-08 to 1988-09-08 | completed | S |
| Stereotactic biopsy of the left frontoparietal lesion: necrotizing inflammation with Toxoplasma gondii organisms; no lymphoma | 1988-09-10 to 1988-09-10 | completed | S |
| 12-lead electrocardiogram: sinus rhythm 72/min, old inferior Q waves, no acute ST change | 1989-01-12 to 1989-01-12 | completed | S |
| Advance care planning conversation, about 20 minutes | 1989-08-17 to 1989-08-17 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1984-05-03 | Tdap vaccine | completed | S |
| 1988-09-18 | Influenza vaccine, 1988-1989 season, given in the hospital | completed | S |
| 1989-01-12 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 1989-01-12 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 1989-01-12 | Meningococcal conjugate vaccine MenACWY, dose 1 of 2 | completed | S |
| 1989-02-09 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 1989-04-13 | Meningococcal conjugate vaccine MenACWY, dose 2 of 2 | completed | S |
| 1989-04-13 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
| 1989-08-17 | Recombinant zoster vaccine, dose 2 of 2 | completed | S |
| 1989-10-19 | Influenza vaccine, 1989-1990 season | completed | S |
| 1989-10-19 | COVID-19 vaccine, 1989-1990 formula | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| July 31, 1979 | Heart attack at age 36 while teaching tennis to young people, followed by quadruple coronary artery bypass surgery | D (CLM-0002) |
| 1983 | Second (double) bypass operation for recurrent chest pain, with a blood transfusion | D (CLM-0003) |
| 1988 | Right-arm weakness from a left-sided brain mass, removed and found to be toxoplasmosis; HIV and AIDS diagnosed, believed to have been acquired from the transfusion during the 1983 operation | D (CLM-0004, CLM-0005) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died at 27 of complications from surgery; atherosclerotic heart disease at an early age reported | D (CLM-0007) | |
| father | Heart attacks at 55 and 59; atherosclerotic heart disease at an early age reported | D (CLM-0007) |
| Concern | Status | Evidence |
|---|---|---|
| He wants to decide for himself who learns of his HIV diagnosis, and when | active | S |
| He wants to keep coaching and playing tennis without putting his heart at risk | active | S |
Most recent measures: HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection 0 on 1989-10-19; CD3+CD4+ (T4 helper) cells [#/volume] in Blood 318 on 1989-10-19; Leukocytes [#/volume] in Blood by Automated count 5 on 1989-10-19; Hemoglobin [Mass/volume] in Blood 14.1 on 1989-10-19; Platelets [#/volume] in Blood by Automated count 236 on 1989-10-19; Sodium [Moles/volume] in Serum or Plasma 140 on 1989-10-19; Potassium [Moles/volume] in Serum or Plasma 4.5 on 1989-10-19; Creatinine [Mass/volume] in Serum or Plasma 1.12 on 1989-10-19; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M 82 on 1989-10-19; Glucose [Mass/volume] in Serum or Plasma 91 on 1989-10-19; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 27 on 1989-04-13; Cholesterol [Mass/volume] in Serum or Plasma 118 on 1989-04-13; Cholesterol in HDL [Mass/volume] in Serum or Plasma 41 on 1989-04-13; Triglyceride [Mass/volume] in Serum or Plasma 125 on 1989-04-13; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 52 on 1989-04-13; Hemoglobin A1c/Hemoglobin.total in Blood 5.4 on 1989-01-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 2 on 1989-07-13; Total score [AUDIT-C] 1 on 1989-08-17; Lipoprotein a [Mass/volume] in Serum or Plasma 24 on 1989-04-13; Hepatitis B virus surface Ab [Units/volume] in Serum 86 on 1989-04-13; Albumin/Creatinine [Mass Ratio] in Urine 12 on 1989-07-13; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 1989-08-17 [S]
Strengths and supports: Supports: married, with a young child, and close friends; has told only a few people about his HIV diagnosis [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| HIV infection, diagnosed about four months before intake with a CD4 count of 58 cells/uL and cerebral toxoplasmosis (an AIDS-defining illness); on antiretroviral therapy since; synthetic modern episode linked to the documented transfusion-acquired infection | active | confirmed | B20 | S — Synthetic modern coding of the documented HIV infection and AIDS diagnosis; B20 stays the code after an AIDS-defining illness, however well the infection is controlled. |
| Cerebral toxoplasmosis, single left-sided lesion with right-hand weakness, diagnosed by stereotactic biopsy; six weeks of acute treatment completed; weakness recovered; on maintenance therapy | active | confirmed | B58.2 | S — Synthetic modern coding of the documented 1988 toxoplasmosis; the modern diagnosis was by biopsy rather than removal of the mass. |
| Coronary artery disease after two bypass operations (quadruple, then double), no angina; synthetic modern episode linked to the documented 1942 and 1946 operations | active | confirmed | I25.10 | S — Synthetic modern diagnosis; the history remains D. |
| Old myocardial infarction at age 36 | active | confirmed | I25.2 | S — Synthetic coded history of the documented 1979 heart attack. |
| Hyperlipidemia, on high-intensity statin | active | confirmed | E78.5 | S — Synthetic diagnosis; no cholesterol value from his lifetime is used. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1989-01-12 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 42 | {copies}/mL | Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected | High | S |
| 1989-01-12 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 156 | /uL | 500-1500 /uL | Low | S |
| 1989-01-12 | Leukocytes [#/volume] in Blood by Automated count | 4.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1989-01-12 | Hemoglobin [Mass/volume] in Blood | 13 | g/dL | 13.2-16.6 g/dL | Low | S |
| 1989-01-12 | Platelets [#/volume] in Blood by Automated count | 198 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1989-01-12 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1989-01-12 | Potassium [Moles/volume] in Serum or Plasma | 4.9 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1989-01-12 | Creatinine [Mass/volume] in Serum or Plasma | 1.18 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1989-01-12 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M | 78 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1989-01-12 | Glucose [Mass/volume] in Serum or Plasma | 92 | mg/dL | 70-99 mg/dL | Normal | S |
| 1989-01-12 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 30 | U/L | 7-56 U/L | Normal | S |
| 1989-01-12 | Cholesterol [Mass/volume] in Serum or Plasma | 158 | mg/dL | <=199 mg/dL | Normal | S |
| 1989-01-12 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 40 | mg/dL | >=40 mg/dL | Normal | S |
| 1989-01-12 | Triglyceride [Mass/volume] in Serum or Plasma | 150 | mg/dL | <=149 mg/dL | High | S |
| 1989-01-12 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 88 | mg/dL | <=99 mg/dL | Normal | S |
| 1989-01-12 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.4 | % | <=5.6% | Normal | S |
| 1989-01-12 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1989-01-12 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 1989-02-09 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1989-02-09 | Potassium [Moles/volume] in Serum or Plasma | 4.8 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1989-02-09 | Creatinine [Mass/volume] in Serum or Plasma | 1.16 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1989-02-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M | 79 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1989-02-09 | Glucose [Mass/volume] in Serum or Plasma | 90 | mg/dL | 70-99 mg/dL | Normal | S |
| 1989-04-13 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | {copies}/mL | Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected | Normal | S |
| 1989-04-13 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 218 | /uL | 500-1500 /uL | Low | S |
| 1989-04-13 | Leukocytes [#/volume] in Blood by Automated count | 4.6 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1989-04-13 | Hemoglobin [Mass/volume] in Blood | 13.6 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1989-04-13 | Platelets [#/volume] in Blood by Automated count | 224 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1989-04-13 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1989-04-13 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1989-04-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.15 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1989-04-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M | 80 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1989-04-13 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 1989-04-13 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 27 | U/L | 7-56 U/L | Normal | S |
| 1989-04-13 | Cholesterol [Mass/volume] in Serum or Plasma | 118 | mg/dL | <=199 mg/dL | Normal | S |
| 1989-04-13 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 41 | mg/dL | >=40 mg/dL | Normal | S |
| 1989-04-13 | Triglyceride [Mass/volume] in Serum or Plasma | 125 | mg/dL | <=149 mg/dL | Normal | S |
| 1989-04-13 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 52 | mg/dL | <=99 mg/dL | Normal | S |
| 1989-04-13 | Lipoprotein a [Mass/volume] in Serum or Plasma | 24 | mg/dL | <=29 mg/dL | Normal | S |
| 1989-04-13 | Hepatitis B virus surface Ab [Units/volume] in Serum | 86 | m[IU]/mL | >=10 m[IU]/mL | Normal | S |
| 1989-07-13 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | {copies}/mL | Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected | Normal | S |
| 1989-07-13 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 262 | /uL | 500-1500 /uL | Low | S |
| 1989-07-13 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1989-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1989-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.14 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1989-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M | 80 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1989-07-13 | Glucose [Mass/volume] in Serum or Plasma | 93 | mg/dL | 70-99 mg/dL | Normal | S |
| 1989-07-13 | Albumin/Creatinine [Mass Ratio] in Urine | 12 | mg/g | <=29 mg/g | Normal | S |
| 1989-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 2 | {score} | S | ||
| 1989-08-17 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 1989-08-17 | Total score [AUDIT-C] | 1 | {score} | S | ||
| 1989-10-19 | HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection | 0 | {copies}/mL | Below 20 copies/mL (limit of quantification); 0 means HIV-1 RNA not detected | Normal | S |
| 1989-10-19 | CD3+CD4+ (T4 helper) cells [#/volume] in Blood | 318 | /uL | 500-1500 /uL | Low | S |
| 1989-10-19 | Leukocytes [#/volume] in Blood by Automated count | 5 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 1989-10-19 | Hemoglobin [Mass/volume] in Blood | 14.1 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 1989-10-19 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 1989-10-19 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 1989-10-19 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1989-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 1.12 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1989-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1984)/1.73 sq M | 82 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1989-10-19 | Glucose [Mass/volume] in Serum or Plasma | 91 | mg/dL | 70-99 mg/dL | Normal | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1989-01-12 | Body height | 185 | cm | S |
| 1989-01-12 | Body weight | 72 | kg | S |
| 1989-01-12 | Body mass index (BMI) [Ratio] | 21 | kg/m2 | S |
| 1989-01-12 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1989-01-12 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1989-01-12 | Heart rate | 72 | /min | S |
| 1989-01-12 | Respiratory rate | 14 | /min | S |
| 1989-01-12 | Body temperature | 36.7 | Cel | S |
| 1989-01-12 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1989-02-09 | Body height | 185 | cm | S |
| 1989-02-09 | Body weight | 72.6 | kg | S |
| 1989-02-09 | Body mass index (BMI) [Ratio] | 21.2 | kg/m2 | S |
| 1989-02-09 | Systolic blood pressure | 116 | mm[Hg] | S |
| 1989-02-09 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1989-02-09 | Heart rate | 70 | /min | S |
| 1989-02-09 | Respiratory rate | 14 | /min | S |
| 1989-02-09 | Body temperature | 36.6 | Cel | S |
| 1989-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1989-04-13 | Body height | 185 | cm | S |
| 1989-04-13 | Body weight | 73.8 | kg | S |
| 1989-04-13 | Body mass index (BMI) [Ratio] | 21.6 | kg/m2 | S |
| 1989-04-13 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1989-04-13 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1989-04-13 | Heart rate | 68 | /min | S |
| 1989-04-13 | Respiratory rate | 14 | /min | S |
| 1989-04-13 | Body temperature | 36.7 | Cel | S |
| 1989-04-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| 1989-07-13 | Body height | 185 | cm | S |
| 1989-07-13 | Body weight | 74.6 | kg | S |
| 1989-07-13 | Body mass index (BMI) [Ratio] | 21.8 | kg/m2 | S |
| 1989-07-13 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1989-07-13 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1989-07-13 | Heart rate | 66 | /min | S |
| 1989-07-13 | Respiratory rate | 14 | /min | S |
| 1989-07-13 | Body temperature | 36.6 | Cel | S |
| 1989-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1989-10-19 | Body height | 185 | cm | S |
| 1989-10-19 | Body weight | 75 | kg | S |
| 1989-10-19 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 1989-10-19 | Systolic blood pressure | 120 | mm[Hg] | S |
| 1989-10-19 | Diastolic blood pressure | 74 | mm[Hg] | S |
| 1989-10-19 | Heart rate | 66 | /min | S |
| 1989-10-19 | Respiratory rate | 14 | /min | S |
| 1989-10-19 | Body temperature | 36.6 | Cel | S |
| 1989-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1989-08-17 | Body height | 185 | cm | S |
| 1989-08-17 | Body weight | 74.8 | kg | S |
| 1989-08-17 | Body mass index (BMI) [Ratio] | 21.9 | kg/m2 | S |
| 1989-08-17 | Systolic blood pressure | 118 | mm[Hg] | S |
| 1989-08-17 | Diastolic blood pressure | 72 | mm[Hg] | S |
| 1989-08-17 | Heart rate | 64 | /min | S |
| 1989-08-17 | Respiratory rate | 14 | /min | S |
| 1989-08-17 | Body temperature | 36.6 | Cel | S |
| 1989-08-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1989-01-12 | Establishing primary care for HIV after a recent diagnosis with cerebral toxoplasmosis, and for coronary artery disease after two bypass operations | finished | S |
| 1989-02-09 | Four-week check of potassium and creatinine, second hepatitis B vaccine, and infectious diseases consultation | finished | S |
| 1989-04-13 | Three-month HIV and lipid review | finished | S |
| 1989-07-13 | Six-month HIV and coronary disease review with depression screening | finished | S |
| 1989-10-19 | Nine-month HIV review: decision to stop toxoplasmosis maintenance therapy | finished | S |
| 1989-08-17 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Antiretroviral therapy with bictegravir, emtricitabine, and tenofovir alafenamide once daily, chosen for its high barrier to resistance and few interactions with his cardiac medicines; viral load and CD4 count every three months | completed | GL-DHHS-ART, GL-IAS-ART-2024, GL-HIVMA-PC-2020 | S |
| Infectious diseases consultation to co-manage HIV: the regimen and its interactions, opportunistic-infection prophylaxis, the monitoring schedule, and vaccines | completed | GL-DHHS-ART, GL-DHHS-OI | S |
| Toxoplasma maintenance therapy with trimethoprim-sulfamethoxazole double strength twice daily, which also prevents Pneumocystis pneumonia, until the CD4 count is above 200 for more than six months on suppressive therapy; blood count, potassium, and creatinine every three months while on it | completed | GL-DHHS-OI | S |
| Secondary prevention of coronary disease after two bypass operations: aspirin, high-intensity atorvastatin with ezetimibe added for an LDL goal below 55 mg/dL, blood pressure below 130/80, a heart-healthy diet, regular exercise, and a written chest-pain plan with sublingual nitroglycerin | completed | GL-CCD-2023, GL-CMID-2026 | S |
| Vaccines for adults with HIV: pneumococcal, hepatitis B with an antibody check afterwards, the two-dose meningococcal ACWY series, recombinant zoster, and seasonal influenza and COVID-19, with no live vaccines while the CD4 count is below 200 | completed | GL-CDC-IMZ-HIV, GL-HIVMA-PC-2020 | S |
| Person-first, confidential care: he decides who learns of his diagnosis; support with disclosure if and when he chooses, peer support, and depression screening with the PHQ-9 at intake and six months and the PHQ-2 at the preventive visit | completed | GL-HIVMA-PC-2020, GL-USPSTF-DEP-2023, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| HIV-1 viral load not detected by the three-month visit | 1989-04-13 | completed | Viral load not detected (below 20 copies/mL) at three months, and at six and nine months | S |
| CD4 count above 200 cells/uL for more than six months with an undetectable viral load, so that maintenance therapy can stop safely | 1989-10-19 | completed | CD4 218 at three months, 262 at six months, and 318 at nine months; trimethoprim-sulfamethoxazole stopped | S |
| LDL cholesterol below 55 mg/dL by the three-month visit | 1989-04-13 | completed | LDL cholesterol 52 mg/dL on atorvastatin and ezetimibe | S |
| Hepatitis B vaccine series completed with a protective antibody level by the three-month visit | 1989-04-13 | completed | Hepatitis B surface antibody 86 mIU/mL | S |
| Keep blood pressure below 130/80 mmHg | 1989-07-13 | completed | Blood pressure 116 to 120 over 72 to 74 at every visit | S |